AstraZeneca's IMFINZI and IMJUDO Show Promise in Liver Cancer Treatment
AstraZeneca has announced positive results from the EMERALD-3 Phase III trial, which evaluated the combination of IMFINZI (durvalumab) and IMJUDO (tremelimumab-actl) with lenvatinib and transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (HCC) eligible for embolization. The trial demonstrated a statistically significant improvement in progression-free survival (PFS) compared to TACE alone. The combination also showed a trend toward improved overall survival, although this was not formally tested at this stage. The STRIDE regimen, which includes single tremelimumab-actl regular interval durvalumab, was used in the investigational arms. The trial will continue to monitor overall survival and other key secondary endpoints. HCC is the most common type of liver cancer, and embolization is a standard procedure for these patients, though many experience disease progression within six to ten months. 
